Anna Wood

MBBS, FRACP, BCom, BA, Endocrinologist, Department of Endocrinology, Royal Darwin Hospital, Darwin, NT; Senior Research Officer, Menzies School of Health Research, Charles Darwin University, Darwin, NT

Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety.